Protiveris, Inc. Received MIPS Award For Technology Optimization 
10/19/2005 5:10:40 PM

ROCKVILLE, Md., April 1 /PRNewswire/ -- Protiveris Inc., a bio- nanotechnology company commercializing bioMEMS technologies to facilitate protein research and the discovery of new pharmaceuticals, today announced that it is a recipient of a $116,000 award from the Maryland Industrial Partnerships (MIPS) program. This award is to be used for the optimization of microfluidic sample delivery system in the VeriScan(TM) 3000 -- the Company's patent pending biosensor system for advanced biological and chemical detection.

Protiveris will work with Dr. Benjamin Shapiro, Assistant Professor at the University of Maryland, and his students to model microfluidic activity in the VeriScan 3000 System. Empirical studies will be completed at the Company's laboratories in Rockville, Maryland.

"We are excited about working with Dr. Shapiro and his students and are grateful to the MIPS program for giving us access to a leader in this highly technical field," said Dr. Robert Cain, Director of R&D at Protiveris. "This partnership will allow us to enhance a critical element of our biosensor system."

Protiveris' protein biochip system and optical reader utilizes arrays of microcantilevers with customizable surfaces to measure distinct biomolecular interactions, including interactions between proteins, antibodies, antigens, or DNA. This robust platform can be used for a variety of biopharmaceutical applications including ligand fishing, comparative protein expression profiling, panel testing, toxicity profiling, and protein expression screening. The chip's sensitivity allows for use of nanoliters of sample volumes, significantly less volume than current technologies, thereby preserving precious reagents such as chemical libraries.

About Protiveris, Inc.

Protiveris is committed to establishing the standard of performance for proteomic research tools. The VeriScan(TM) 3000 bench top biochip system detects, measures and analyzes biomolecular and chemical interactions to enable more efficient and accurate research outcomes. The biochip utilizes arrays of microcantilevers with customizable surfaces to detect interactions between proteins, antibodies, antigens, or DNA. This label-free system provides researchers with the ability to create high content assays that deliver real time data. More information about Protiveris, their technology, products, and services can be found at the company's web site at

About Maryland Industrial Partnerships

The Maryland Industrial Partnerships (MIPS) program accelerates the commercialization of technology in Maryland by providing matching funds for collaborative R&D projects between companies and University System of Maryland faculty. From the 10th top-selling biotech drug in the world to an infant formula additive licensed to more than 60 percent of the world's infant formula manufacturers, MIPS-supported products have generated more than $300 million in sales, indirectly added jobs to the region, and infused state-of- the-art technology into the global marketplace. Additional information about the Maryland Industrial Partnerships program can be found at

Protiveris Inc.

CONTACT: Robert Menzi, Chief Operating Officer of Protiveris Inc.,+1-301-738-7800, or